Clinical Trial Update: PRO1107 in Patients With Advanced Solid Tumors [Phase 1, Phase 2]

View source ↗

Summary

The Phase 1/2 PRO1107 trial in advanced solid tumors, including endometrial and ovarian cancers, has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Endometrial Cancer
• Gastroesophageal Cancer
• Non-small Cell Lung Cancer
• Ovarian Cancer
• Triple-negative Breast Cancer
• Urothelial Carcinoma

Drugs mentioned

• PRO1107

Snippet

Sponsor: Genmab | Conditions: Endometrial Cancer, Ovarian Cancer | Phase 1, Phase 2 | Status: TERMINATED